Global Viral Partnering 2012-2018: Comprehensive Access to Over 3500 Viral Deal Records

DUBLIN, March 12, 2018 /PRNewswire/ --

The "Global Viral Partnering 2012-2018: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

Global Viral Partnering 2012 to 2018 provides the full collection of Viral disease deals signed between the world's pharmaceutical and biotechnology companies since 2012.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Viral disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Viral deals.

The report presents financial deal terms values for Viral deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

In addition, a comprehensive appendix is provided with each report of all Viral partnering deals signed and announced since 2012. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Viral technologies and products.

Report scope

Global Viral Partnering 2012 to 2018 includes:

• Trends in Viral dealmaking in the biopharma industry since 2012
• Analysis of Viral deal structure
• Access to headline, upfront, milestone and royalty data
• Access to hundreds of Viral deal contract documents
• Comprehensive access to over 3500 Viral deal records
• The leading Viral deals by value since 2012
• Most active Viral dealmakers since 2012

The report includes deals for the following indications:

Viral: Common cold, Cytomegalovirus, Ebola, FIV, Foot and mouth disease, Hepatitis A, B, C, D, Herpes simplex, HIV, Influenza, H5N1 (Avian Flu), H1N1 (Swine Flu), Japanese encephalitis, Polio, Respiratory syncytial virus (RSV), Zika, plus other viral indications.

Deals and contracts are listed by:

• Headline value
• Upfront payment value
• Royalty rate value
• Stage of development at signing
• Deal component type
• Technology type
• Specific therapy indication
  

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Viral dealmaking

2.1. Introduction
2.2. Viral partnering over the years
2.3. Viral partnering by deal type
2.4. Viral partnering by industry sector
2.5. Viral partnering by stage of development
2.6. Viral partnering by technology type
2.7. Viral partnering by therapeutic indication

Chapter 3 -Financial deal terms for Viral partnering

3.1. Introduction
3.2. Disclosed financials terms for Viral partnering
3.3. Viral partnering headline values
3.4. Viral deal upfront payments
3.5. Viral deal milestone payments
3.6. Viral royalty rates

Chapter 4 - Leading Viral deals and dealmakers

4.1. Introduction
4.2. Most active in Viral partnering
4.3. List of most active dealmakers in Viral
4.4. Top Viral deals by value

Chapter 5 - Viral contract document directory

5.1. Introduction
5.2. Viral partnering deals where contract document available

Chapter 6 - Viral dealmaking by therapeutic target

6.1. Introduction
6.2. Deals by Viral therapeutic target

Appendices

Appendix 1 - Directory of Viral deals by company A-Z 2012 to 2018
Appendix 2 - Directory of Viral deals by deal type 2012 to 2018
Appendix 3 - Directory of Viral deals by stage of development 2012 to 2018
Appendix 4 - Directory of Viral deals by technology type 2012 to 2018

For more information about this report visit https://www.researchandmarkets.com/research/j6zxfb/global_viral?w=5

Media Contact:

Laura Wood, Senior Manager
[email protected]  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets